Real-world implementation of pertuzumab from 2013 to 2023 for de Novo HER2-positive metastatic breast cancer in the Netherlands: a population-based study
Nan Ding, Sandra M.E. Geurts, Ingeborg J.H. Vriens, Renée Visserman, Thiemo J.A. van Nijnatten, Marjolein Smidt, Adri C. Voogd, Janneke Verloop, Vivianne C.G. Tjan-Heijnen · 2026
Read Real-world implementation of pertuzumab from 2013 to 2023 for de Novo HER2-positive metastatic breast cancer in the Netherlands: a population-based study by Nan Ding, Sandra M.E. Geurts, Ingeborg J.H. Vriens, Renée Visserman, Thiemo J.A. van Nijnatten, Marjolein Smidt, Adri C. Voogd, Janneke Verloop, Vivianne C.G. Tjan-Heijnen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13450629.txt.
Description
Nan Ding and co-authors track in 2026 how a targeted breast cancer drug spread through Dutch care over a decade. The drug, pertuzumab, is used for cancers that carry the HER2 mark and have already spread at first find. Registry data covered 1,982 such patients who got drug treatment between 2013 and 2023.
Use climbed from under a tenth of patients in the first year to about four fifths by 2018, then held flat. Older patients and those with lower incomes or hormone-linked tumors got the drug less often in the flat years. The authors say the gaps point policy makers to where equal access still fails.
Catalog record
| CREATOR | Nan Ding, Sandra M.E. Geurts, Ingeborg J.H. Vriens, Renée Visserman, Thiemo J.A. van Nijnatten, Marjolein Smidt, Adri C. Voogd, Janneke Verloop, Vivianne C.G. Tjan-Heijnen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40049 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |